1. Abbvie is Buying Botox-Maker Allergan in a $63 Billion Pharma Mega-Deal

    Abbvie is Buying Botox-Maker Allergan in a $63 Billion Pharma Mega-Deal
    • AbbVie has agreed to buy Allergan in a $63 billion cash-and-stock deal.
    • Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share that they hold, totaling $188.24 per Allergan share.
    • The offer represents a 45% premium to the closing price of Allergan's shares on Wednesday...
    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
  2. Quotes

    1. With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone.
  3. Topics Mentioned

  4. Authors